We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dopamine Receptor Ligand Selectivity—An In Silico/In Vitro Insight.
- Authors
Zell, Lukas; Bretl, Alina; Temml, Veronika; Schuster, Daniela
- Abstract
Different dopamine receptor (DR) subtypes are involved in pathophysiological conditions such as Parkinson's Disease (PD), schizophrenia and depression. While many DR-targeting drugs have been approved by the U.S. Food and Drug Administration (FDA), only a very small number are truly selective for one of the DR subtypes. Additionally, most of them show promiscuous activity at related G-protein coupled receptors, thus suffering from diverse side-effect profiles. Multiple studies have shown that combined in silico/in vitro approaches are a valuable contribution to drug discovery processes. They can also be applied to divulge the mechanisms behind ligand selectivity. In this study, novel DR ligands were investigated in vitro to assess binding affinities at different DR subtypes. Thus, nine D2R/D3R-selective ligands (micro- to nanomolar binding affinities, D3R-selective profile) were successfully identified. The most promising ligand exerted nanomolar D3R activity (Ki = 2.3 nM) with 263.7-fold D2R/D3R selectivity. Subsequently, ligand selectivity was rationalized in silico based on ligand interaction with a secondary binding pocket, supporting the selectivity data determined in vitro. The developed workflow and identified ligands could aid in the further understanding of the structural motifs responsible for DR subtype selectivity, thus benefitting drug development in D2R/D3R-associated pathologies such as PD.
- Subjects
UNITED States. Food &; Drug Administration; DOPAMINE receptors; G protein coupled receptors; DRUG discovery; PARKINSON'S disease; DRUG development
- Publication
Biomedicines, 2023, Vol 11, Issue 5, p1468
- ISSN
2227-9059
- Publication type
Article
- DOI
10.3390/biomedicines11051468